Feature | Intensity Modulated Radiation Therapy (IMRT) | October 20, 2015

Image-guided IMRT Reduces Bowel Side Effects in Cervical Cancer Patients

More targeted radiation therapy found to lessen reported moderate-to-severe toxicity compared to 3-D conformal RT

image-guided IMRT, IG-IMRT, bowel side effects, cervical cancer patients, ASTRO 2015

October 20, 2015 — For cervical cancer patients undergoing postsurgical radiation therapy, image-guided intensity-modulated radiation therapy (IG-IMRT) resulted in a 14 percent reduction in moderate-to-severe bowel side effects when compared to conventional three-dimensional conformal radiation therapy (3-D CRT). This conclusion was supported by research presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.

Post-operative pelvic radiation therapy is the current standard of care for many patients with cervical cancer, yet may affect surrounding organs and tissue and be associated with long-term gastrointestinal side effects. IG-IMRT uses technology to manipulate beams of radiation to conform to the shape of a tumor, thus allowing clinicians to limit exposure to surrounding tissue.

The phase III randomized clinical trial, conducted at Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre in Mumbai, India, included 240 patients, ages 18 and over who were undergoing adjuvant chemoradiation therapy (combined chemotherapy and radiation therapy) and had no pre-existing bowel disease or injury.

This planned interim analysis of the study assessed 117 of the patients who had completed an average of 20-months follow-up (range: two to 46 months). Patients were categorized into two groups: Fifty-six patients received 3-D CRT and 61 patients received IG-IMRT. Patient groups were randomized and had similar treatment histories, with 41.3 percent (23 patients) of the 3-D CRT group having radical hysterectomies and 43.5 percent (27 patients) of the IG-IMRT group having radical hysterectomies. Additionally, 91.8 percent (51 patients) of the 3-D CRT group had chemoradiation therapy, with 85.5 percent (52 patients) of the IG-IMRT group undergoing chemoradiation therapy. RT included 50 Gy, administered over 25 treatments in a five-week timeframe. CRT patients received Cisplatin (40 mg/m2) congruently. This was followed by two fractions of brachytherapy (cylinder based intravaginal brachytherapy) of 6 Gy each.

Patients randomized to the 3-D CRT group received treatment on a linear accelerator, and the IG-IMRT patients received treatment using tomotherapy. Strict constraints were applied in the administration of the IG-IMRT to ensure that no more than 200 cc and 100 cc of small bowel received 15 and 40 Gy respectively.

At each follow-up visit, patients’ bowel side effects were recorded by clinicians using 11 symptom scales of Common Toxicity Criteria for Adverse Events (CTCAE version 3.0). In the 3-D CRT group, 58.9 percent (33 patients) experienced =2 acute bowel toxicity (indicating moderate to severe diarrhea, vomiting, nausea, lower abdominal distension or pain) compared to 54 percent (33 patients) in the IG-IMRT group (p=0.59). The reported late grade =2 bowel toxicity was 25 percent (14 patients) in the 3-D CRT group and 11.4 percent (7 patients) in the IG-IMRT group (p=0.13); and the late grade =3 bowel toxicity (indicating severe diarrhea, lower abdominal pain, subacute intestinal obstruction requiring medical or surgical intervention, bowel perforation or death) was 17.6 percent (10 patients) in the 3-D CRT group and 3.2 percent (2 patients) in the IG-IMRT group (p=0.02). Further, research indicated that neither the surgery type nor the administration of CRT had an impact on bowel side effects.

 “These initial results of this interim analysis are encouraging and trend toward possibly a clinically important reduction in moderate-to-severe bowel side effects with the use of IG-IMRT, however at interim analysis the results are statistically nonsignificant,” said Supriya Chopra, M.D., lead study author and associate professor of radiation oncology at ACTREC, Tata Memorial Centre in Mumbai, India. “While we evaluated patients with cervical cancer in this trial, a significant proportion of patients with other cancers undergo postoperative pelvic radiation worldwide. Therefore, the results of this trial could impact the choice of future radiation delivery technique for various pelvic malignancies.”

For more information: www.astro.org

Related Content

Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Category A

Category A

Feature | Breast Density | April 03, 2020 | By Dayna Williams M.D., Shivani Chaudhry, M.D., and Laurie R. Margolies, M.D.
Breast cancer is the most common cance
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 New studies use SIRD model to forecast COVID-19 spread; examine patient CT scans to correlate clinical features with mortality

Fig 1. A sample scoring on CT images of a 63-year-old woman from mortality group demonstrated a total score of 63. It was calculated as: for upper zone (A), 3 (consolidation) × 3 (50–75% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) ×1 (< 25% distribution) × 2 (both right and left lungs); for middle zone (B), 3 (consolidation) × 2 (25–50% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) × 2 (25–50% distribution) × 2 (both right and left lungs); for lower zone (C), 3 (consolidation) × (2 (25–50% distribution of the right lung) + 3 (50–75% distribution of the left lung)) + 2 (ground glass opacity) × (2 (25–50% distribution of the right lung) + 1 (< 25% distribution of the left lung)) Yuan et al, 2020 (CC BY 4.0)

News | Coronavirus (COVID-19) | April 01, 2020
April 1, 2020 — A new study, ...
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Mammography | March 25, 2020
March 25, 2020 — The...
The 2020 Society of Breast Imaging/American College of Radiology (SBI/ACR) annual symposium has been cancelled, and the event rescheduled for April 8-11, 2020, in Savannah, Ga. #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SBI20
News | Society of Breast Imaging (SBI) | March 16, 2020
March 16, 2020 — The 2020 Society of Breast Imaging/American College of Radiology (...
A University of Colorado Cancer Center study published in the Journal of the National Cancer Institute shows an important predictor of PET-CT use

Rustain Morgan, M.D., and colleagues show racial/ethnic disparities in use of important imaging during lung cancer diagnosis. Photo courtesy of University of Colorado Cancer Center

News | PET-CT | March 12, 2020
March 12, 2020 — The use of PET-CT